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Umbilical cord blood (CB) is a convenient and
broadly used source of hematopoietic stem cells
(HSCs) for allogeneic stem cell transplantation. How-
ever, limiting numbers of HSCs remain a major
constraint for its clinical application. Although one
feasible option would be to expand HSCs to
improve therapeutic outcome, available protocols
and the molecular mechanisms governing the self-
renewal of HSCs are unclear. Here, we show that
ectopic expression of a single microRNA (miRNA),
miR-125a, in purified murine and human multipo-
tent progenitors (MPPs) resulted in increased
self-renewal and robust long-term multi-lineage re-
population in transplanted recipient mice. Using
quantitative proteomics and western blot analysis,
we identified a restricted set of miR-125a targets
involved in conferring long-term repopulating capac-
ity to MPPs in humans and mice. Our findings offer
the innovative potential to use MPPs with enhanced
self-renewal activity to augment limited sources of
HSCs to improve clinical protocols.
INTRODUCTION
Allogeneic stem cell transplantation is an established treatment
for malignant diseases such as leukemia, myelodysplasia, and
myelofibrosis as well as non-malignant disorders such as severe
aplastic anemia and congenital immune or enzyme deficiencies,Cell Swith >40,000 transplants undertaken worldwide (Aljurf et al.,
2014; Pineault and Abu-Khader, 2015). Despite this success,
67% of patients who require allogeneic transplantation are
not able to undergo this procedure due to the lack of matched
donors (Oran and Shpall, 2012). Umbilical cord blood (CB) banks
have the potential to alleviate these obstacles due to broader
representation of histocompatibility leukocyte antigen (HLA)
types, less restriction on HLA matching, reduced incidence of
graft versus host disease (GvHD), and rapid access compared
to registries. However, widespread use of CB is impaired due
to insufficient hematopoietic stem cell (HSC) numbers in single
CB units, resulting in extended times to full engraftment (Ballen
et al., 2013). Transplants combining two unrelated CB units
have attempted to overcome the shortfall in HSC number,
although improvements are modest (Barker et al., 2001; Wagner
et al., 2014). Multiple efforts have been undertaken to attempt
HSC expansion, but these have largely been empirical and rarely
successful (Metcalf, 2008; Ogawa, 1993; Sauvageau et al.,
2004). Recently, promising HSC expansion protocols have
employed small molecules such as prostaglandin E2, SR1,
UM171, or UM729, although clinical efficacy remains elusive
(Boitano et al., 2010; Fares et al., 2014; North et al., 2007).
The unique self-renewal properties of HSCs are thought to be
controlled by a combination of intrinsic and extrinsic signaling
networks that finely balance the equilibrium among quiescence,
proliferation, and differentiation. Generating increased numbers
of HSC could come from controlling self-renewal or inducing
self-renewal in the more numerous progenitor compartment.
To achieve the latter, numerous signaling pathways would
have to be appropriately fine-tuned. Small, non-coding RNAs
such as microRNAs (miRNAs) act as post-transcriptional regula-
tors of gene expression, and one miRNA can target hundreds of
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Figure 1. Enforced Expression of miR-125a Gives a Proliferative Advantage to HSCs
(A) RT-PCR expression levels of miR-125a in flow-sorted populations from the human LinCB hierarchy. Cells were sorted to high purity according to the scheme
outlined in Figure S1A. RNU48 was used as an endogenous control, and miR-125a levels were normalized to RNU48 levels.
(B) The scheme describing the experimental system.
(C) Human mOrange+ (mO+) chimerism at 12 and 24 weeks post-transplantation with pre-sorted CD34+CD38 umbilical cord blood cells transduced with a miR-
125 lentiviral vector (miR-125OE) (n = 10) or an empty control vector (n = 10) in injected femur (IF) and distant bone marrow (BM) sites. Red and gray symbols
represent replicate experiments using two distinct human CB pools. Color-matched bars represent input levels of mOrange+ cells at time of transplant for each
experiment.
(D) Lineage distribution of mO+ BM grafts 12 and 24 weeks post-transplantation.
(E) Frequency of CMP, GMP, and MEP populations recovered from total BM within the CD34+CD38+ committed progenitor compartment.
(F) Proportion of HSC, MPP, and MLP from total BM within the CD34+CD38 primitive compartment 12 and 24 weeks post-transplant.
(legend continued on next page)
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positioning miRNAs as pivotal regulators of cellular homeostasis
(Bartel, 2009; Filipowicz et al., 2008). miRNA profiling of hemato-
poietic stem and progenitor cells (HSPCs) has identified several
miRNAs as differentially expressed and functionally able to
govern HSC properties (Gerrits et al., 2012; Lechman et al.,
2012; O’Connell et al., 2008, 2010). The family of miR-125 is
particularly interesting, as they are highly expressed in murine
HSCs (Gerrits et al., 2012; Guo and Scadden, 2010; O’Connell
et al., 2010). This family consists of three paralogs (miR-125a,
miR-125b1, andmiR-125b2) sharing an identical seed sequence
and exerting similar effects on HSPCs (Wojtowicz et al., 2014).
MicroRNA-125a expression levels significantly decrease upon
hematopoietic differentiation in mice (Gerrits et al., 2012; O’Con-
nell et al., 2010), implying a correlation between the level of miR-
125 activity and differentiation status. Ectopic expression of
miR-125 (a, b1, or b2) in murine bone marrow (BM) cells results
in an increased self-renewal, a proliferative advantage to HSCs
and the initiation of myeloproliferation or leukemia, depending
on miR-125 expression level (O’Connell et al., 2010; Wojtowicz
et al., 2014). Targeted downregulation of miR-125a and miR-
125b caused reduced HSPC self-renewal in vitro (Guo and
Scadden, 2010) and reduced proliferation and blood cell output
in vivo (Ooi et al., 2010; Wojtowicz et al., 2014), confirming a
pivotal role for miR-125 family members in the molecular control
of HSC self-renewal.
In the current study, we explored the potential of a single
miRNA, miR-125a, to confer long-term repopulating ability to
non-stem cell populations. Here, we report that enforced
expression of miR-125a endows multipotent progenitors
(MPPs) with enhanced self-renewal potential, offering an innova-
tive means to use MPPs to augment limited sources of HSCs to
improve clinical outcomes.
RESULTS
Enforced Expression of miR-125a Increases Human
HSC Self-Renewal
Since miR-125a is highly expressed within mouse long-term
HSCs (LT-HSCs) and has been shown to increase their self-
renewal activity (Gerrits et al., 2012; Guo and Scadden, 2010;
O’Connell et al., 2010; Ooi et al., 2010; Wojtowicz et al., 2014),
we wanted to evaluate if these attributes are evolutionarily
conserved within human hematopoiesis. We sorted immunophe-
notypically defined HSC and progenitor cell subsets from hu-
man-lineage-depleted CB (Figure S1A) (Doulatov et al., 2010;
Notta et al., 2011) to obtain a detailed expression profile ofmature
miR-125a. We observed that the highest expression levels of
miR-125a were restricted to the HSC-enriched CD34+CD38
CD45RACD90+CD49f+ and CD34+CD38CD45RACD90
CD49f (MPP) fractions and become significantly downregulated
in multi-lymphoid progenitors (MLPs) and committed CD34+
CD38+ progenitor fractions (common myeloid progenitor [CMP],
granulocyte monocyte progenitor [GMP], and megakaryocytic-
erythroid progenitor [MEP]) (Figure 1A). These data demonstrate(G) Secondary transplantations. BM cells were harvested from two primary recipie
by limiting dilution transplantation into secondary mice. Confidence intervals we
All data reflect mean values ± SEM. Statistical significance was assessed us
***p < 0.001.an inverse correlation between differentiation state and miR-
125a expression levels.
To study the function ofmiR-125a in humanHSPCs, we gener-
ated a lentiviral vector with miR-125a (miR-125OE) under a
constitutive SFFV promoter using an orange fluorescent protein
(OFP) reporter (Figure 1B). To determine the impact of increased
miR-125a expression (Figure S1B) on human HSPC function,
CD34+CD38 human CB HSPCs transduced with miR-125OE
and control vector transduced cells were analyzed in xenotrans-
plantation assays (Figure 1B). At 12 and 24 weeks after
transplantation, we observed significant increases in human
chimerism within distant BM sites in the miR-125aOE group
compared to controls; chimerism levels in the injected femur
(IF) were significantly increased only at 12 weeks (Figure 1C).
Mice transplanted with miR-125OE cells also exhibited white
BM and splenomegaly (Figure S1C). Furthermore, within
enlarged spleens, we found increased proportions of CD19+
CD10+CD20 B lymphoid cells, suggesting a partial B cell differ-
entiation block at the pro-B cell stage (Figure S1D). Examination
of the lineage distribution of OFP+ cells in the BM revealed that all
lineages were present, with significant expansion of the CD41+
megakaryocyte population (Figure 1D) and an increased CD3+
T cell population. At the progenitor level (Figures 1E and S1E),
we observed a trend for increased GMPs and decreased MEP
frequency in the BM, whereas the frequency of the multi-
lymphoid progenitor fraction (MLP) was significantly increased
at the expense of immunophenotypic HSCs and MPPs in the
primitive compartment (Figures 1F andS1E). These observations
are in line with previous reports inmurine HSPCs pointing to con-
servation of function across species (Gerrits et al., 2012; Guo
and Scadden, 2010; O’Connell et al., 2010).
The self-renewal potential of transduced human HSC within
primary engrafted mice was assessed using quantitative sec-
ondary transplantation assays. Recipients transplanted with
miR-125OE cells showed higher chimerism levels compared to
controls, and the HSC frequency increased by 4.4- and 5-fold
in miR-125OE recipients in independent experiments (Figures
1G and S1F), similar to published murine studies (Gerrits et al.,
2012; Guo and Scadden, 2010; O’Connell et al., 2010).
Enforced Expression of miR-125a Confers a Stem Cell-
like Program to Human CD34+CD38+ Committed
Progenitors and MPPs
Given the robust increase in HSC frequency upon miR-125a
expression, we asked whether more committed cell popula-
tions might also be endowed with enhanced self-renewal.
We flow sorted CD34+CD38 compartment sub-populations
(HSC,MPP, andMLP) andCD34+CD38+ committed progenitors,
transduced them with miR-125OE or control vectors, and
transplanted cells into immuno-deficient mice measuring repo-
pulation after 12 weeks. miR-125a overexpression in CD34+
CD38+ progenitors produced a substantial graft that dissemi-
nated to distant BM locations after 12 weeks, whereas control
transduced CD34+CD38+ cells generated a barely discernablents and flow sorted for hCD45+mO+ cells. Stem cell frequencies were evaluated
re calculated using ELDA software.
ing a non-parametric Mann-Whitney test, where *p < 0.05, **p < 0.01, and
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graft (in onemouse recipient only) in the IF site (Figure 2A). As ex-
pected, only control transduced cells from sorted HSC (CD34+
CD38CD45RACD90+CD49f+) generated a disseminating graft
in recipient mice (Figure 2B). Similarly, sorted HSCs and MPPs
(CD34+CD38CD45RACD90CD49f) transduced with miR-
125OE generated robust engraftment within the IFs and distant
BM locations (Figure 2B). Sorted and transduced MLP (CD34+
CD38CD45RA+) were unable to generate any detectable graft
(Figure 2B). In all cases, xenografts generated by CD34+CD38+
and MPP transduced with miR-125OE showed multi-lineage re-
population (Figures 2C and 2D). To evaluate if the grafts derived
from CD34+CD38+ committed progenitors and MPP were dura-
ble, we transplanted these cells into secondary recipients.
Whereas control transduced progenitors did not generate a graft
in secondary recipient mice, the CD34+CD38+ and MPP cells
that overexpressed miR-125a generated a multi-lineage graft
for 20 weeks (five out of seven and six out of ten mice, respec-
tively; Figures 2E and 2F). Furthermore, MPP secondary grafts
remained multi-lineage (Figure 2G), and in no case did we
observe myeloproliferative disease or leukemia in mice en-
grafted with miR-125OE human CB cells. Finally, to evaluate
the long-term self-renewal potential of miR-125a expressing
MPP, we transplanted the secondary MPP grafts into tertiary re-
cipients for another 10 weeks. After a total of 30 weeks in mice,
we observed small but measurable multi-lineage grafts both
from CD34+CD38 CB progenitors and MPP-expressing miR-
125a (Figures S2A–S2D).
To distinguish between rare contaminating HSCs or enhanced
self-renewal of MPPs as the primary mechanism for the
observed MPP phenotype in secondary and tertiary mice, we
used a modified splinkerette PCR approach to assess the clon-
ality of secondary miR-125OE MPP grafts. Our data demon-
strate that miR-125OE MPP BM grafts were oligoclonal, with
no lentivirus insertions near or within strong oncogenes (Table
S1), suggesting that the enhanced self-renewal observed in
miR-125OE MPP mice was not attributable to rare contami-
nating HSCs. Given that our data strongly suggests that MPPs
are frequently endowed with enhanced self-renewal potential,
we should be able to model this phenomenon at the clonal level.
Using in vitro long-term culture initiating cell (LTC-IC) assays that
were established with presorted transduced MPP (Table S2), we
found that miR-125OE increased the LTC-IC frequency of
transduced MPPs by 4-fold compared to controls (1/11.9
versus 1/44.7, respectively, p = 0.0000000975), with a concom-
itant9-fold increase in colonies/LTC-IC (6.6 ± 2.1 versus 54.4 ±
11.6, p = 0.0041). Together, these data strongly suggest that the
enhancement of self-renewal by enforced expression of miR-
125 occurs not only in HSCs but also in MPPs and in an as-
yet-unidentified population within the CD34+38+ committed
progenitor compartment.
miR-125a Expression Prolongs Self-Renewal Activity in
Murine MPPs
To assess whether this enhanced self-renewal induced by miR-
125a is conserved in mice, we overexpressed miR-125a (Fig-
ure 3A) in LinSca-1+c-Kit+ cells, depleted from CD150+CD48
cells (hereafter referred as progenitors) and in LT-HSCs (Lin
Sca-1+c-Kit+CD150+CD48) (Figure S3A). We confirmed en-
forced overexpression by qPCR (Figure S3B) and performed a386 Cell Stem Cell 19, 383–396, September 1, 2016series of in vivo HSC assays. As controls, we included cells
transduced with a vector expressing only GFP and a vector ex-
pressing a mutant form of miR-125a, where the fourth base of
the seed sequence was modified (for a seed 50-CCCTGAC-30
miR-125mut4T/C) (Figure 3A). The mutant construct was as
effectively expressed and processed as non-mutated miR-
125a (Figure S3B). We competitively transplanted transduced
cells in limiting dilution to lethally irradiated recipients together
with a high dose of 23 106 fresh BM cells (Figure 3A) and moni-
tored GFP+ chimerism over time. As expected, miR-125OE in
LT-HSCs strongly increased their competitive reconstitution ac-
tivity compared to controls, similar to what we and others have
reported (Figure 3B) (Gerrits et al., 2012; Guo and Scadden,
2010; O’Connell et al., 2010; Ooi et al., 2010; Wojtowicz et al.,
2014) and similar to our results using human cells. Control trans-
duced progenitors (and the mutant construct; data not shown)
were unable to provide long-term repopulation (Figure 3C). By
contrast, miR-125OE progenitors generated robust, high levels
of multi-lineage reconstitution up to 16 weeks post-transplanta-
tion (Figure 3C). Limiting dilution experiments demonstrated a
10-fold expansion of stem cell pool size (Figures 3D, 3E, and
S4A). Importantly, miR-125OE progenitors sustained long-term
blood cell production with an estimated frequency similar to con-
trol LT-HSCs (Figures 3D, 3E, and S4A). Using cellular barcoding
(for gene transfer efficiency and cell doses, see Figure S4B), we
observed a significant increase in the number of clones contrib-
uting to myeloid engraftment upon miR-125a overexpression,
indicating that induction of stem cell activity in progenitors
was not a rare event, and likely not from contamination of
rare LT-HSC (Figure 3F). At week 20 post-transplantation, we
observed a reduced number of clones compared to week 4,
but overall, the numbers of contributing clones were comparable
in all groups (Figure 3F). Similar to our human CB data, mouse
125OE progenitors were able to sustain multi-lineage potential
with myeloid skewing represented by increased numbers of
Gr-1+ cells (Figure 3G) and increased numbers of GMPs, at the
expense of MEPs (Figure 3H).
To assess the potential of miR-125a to induce self-renewal, we
serially transplanted 107 BM cells from primary recipients into
lethally irradiated secondary recipients. While the repopulating
potential of control LT-HSCs in secondary recipients was
restricted to short-term engraftment (up to 6 weeks, most prob-
ably due to the high dose of competitors used in the first round
of transplantation), the secondary recipients transplanted with
miR-125OE LT-HSCs or progenitors were highly reconstituted,
with an increased frequency of myeloid cells 20 weeks post-
transplantation in peripheral blood (Figures 4C and 4D). No
lethality was observed in primary recipients. However, in sec-
ondary mice, we observed 20% mortality, starting at week
32, in mice transplanted with either miR-125OE LT-HSC or pro-
genitors. Necropsy revealed increased white blood cell (WBC)
counts, splenomegaly, pale bones, and blast-like cells in the
blood. Fluorescence-activated cell sorting (FACS) analysis of
BM and spleen revealed dominance of EGFP+ cells of myeloid
origin (Gr-1+ and/or Mac-1+, a MPN-like phenotype, as previ-
ously described; Gerrits et al., 2012; data not shown). In tertiary
recipients, mortality further increased to 40% for 125OE pro-
genitors, and 60% for 125OE LT-HSCs. Surviving mice in the
tertiary transplantation showed no engraftment (Figure 4E). In
IF BM IF BM IF BM
HSC MPP MLP




















































Figure 2. miR-125a-Enforced Expression Improves the Repopulating Abilities of MPPs and CD34+CD38+ Committed Progenitors
(A) Human mO+ chimerism at 12 weeks post-transplantation with pre-sorted CD34+CD38+ committed progenitor compartment from human cord blood
transduced with control or miR-125a expressing lentivectors. Red and gray symbols represent replicate experiments using two distinct human CB pools. Color-
matched bars represent input levels of mOrange+ cells at time of transplant for each experiment.
(B) HumanmO+ chimerism at 12weeks post-transplantation with pre-sorted HSC,MPP, andMLP human cord blood populations transducedwith control or miR-
125a expressing lentivectors.
(C) Lineage distribution of mO+ BM grafts from transplanted CD34+CD38+ CB cells 12 weeks post-transplantation.
(D) Lineage distribution of mO+ BM grafts from transplanted MPP 12 weeks post-transplantation.
(E) Human mO+ chimerism at 8 weeks post-secondary transplant from CD34+CD38+ progenitors from primary mouse recipients.
(F) Human mO+ chimerism at 8 weeks post-secondary transplant from MPP from primary mouse recipients.
(G) Lineage distribution of mO+ BM grafts from MPP secondary recipient mice.
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addition, mice transplanted with 125OE progenitors exhibited
an increased fraction of erythroid progenitors (Figures S5A
and S5B). These data suggest that both LT-HSCs and progeni-
tors overexpressing miR-125a remained functionally active for
significantly longer periods of time compared to control cells
(Figure 4F), and the cell type distribution of GFP+ cells in second-
ary recipients 20 weeks post-transplantation showed myeloid
skewing in mice transplanted with LT-HSC overexpressing
miR-125a.
We postulated that the myeloproliferative disease observed
within 125OE mice could be due to a combination of miR-125-
induced intrinsic changes and replicative stress (Figure 4E). To
explore the role of replicative stress, we transplanted control
and miR-125OE LT-HSCs into non-irradiated W41 recipients
(Figure 4G). During the 11-month follow-up period, chimerism
levels in 125OE LT-HSCs increased from 26% at transplantation
reaching upward of 90% after 9 weeks post transplantation
and remained very high. In contrast, the contribution of control
LT-HSCs was stable over time, starting at 30% and slightly
decreasing to 20% at week 45 (Figure 4H). In this non-irradiated
model, we observed only 40% mortality in mice transplanted
with miR-125OE HSC, a 50% reduction compared to serial
transplantation,where replicative stress is augmented (Figure 4I).
These data suggest that replicative stress, due to irradiation and
accompanying cytokine storm, contributes to the development
of myeloproliferative disease in 125OE murine cells.
As recently reported, miR-125a overexpression leads to
changes in expression of several HSC markers, including
Sca-1, c-Kit, and CD150, precluding standard LT-HSC isolation
from repopulated mice (O’Connell et al., 2010; Wojtowicz et al.,
2014). To determine which cell population contained secondary
repopulating potential, we harvested BM cells from reconsti-
tuted primary recipients and sub-fractionated GFP+ Lin cells
into four populations (Figures 4J and 4K). Sub-fractionated cells
from primary recipients were transplanted with competitor
cells into secondary recipients (see Figures 4J, 4K, and S5C
for transplanted cell doses). Repopulating activity in miR-125-
overexpressing cells was exclusively observed in LSK+ and
LS+Kmid cells derived from LT-HSC and in LSK+ cells if pro-
genitors were used (Figures 4J and 4K). Taken together, these
data show thatmiR-125a overexpression interferes withmarkers
expression and cells with the repopulating potential are present
in LSK+ and/or LS+Kmid cell populations upon miR-125a
overexpression.Figure 3. miR-125a Overexpression in Mouse LT-HSC and Progenitors
(A) Experimental setup.
(B) Chimerism levels in Gr-1+ cells in primary recipients transplanted with LT-HSCs
or LT-HSCs with miR-125a (n = 16). Panels also show the absolute cell numbers o
FACS at indicated time points.
(C) Chimerism levels in recipients transplanted with progenitors overexpressing c
points.
(D) Stem cell frequencies in mice transplanted with virally transduced LT-HSCs or
were calculated using ELDA software. The colors indicate the various experimen
(E) The table containing the upper and lower confidence interval and estimated f
(F) The number of detected barcodes in peripheral blood in Gr-1+ cells at 4 or 20
(G) Lineage distribution in GFP+ peripheral blood cells.
(H) Progenitor (LSK+) distribution LinGFP+ BM cells.
Data in (E)–(H) reflect mean values ± SD. Statistical significance was assessed
***p < 0.001.SILAC Reveals a miR-125a-Specific Network of Targets
To gain more insight in the molecular network of miR-125a tar-
gets, we performed stable isotope labeling by amino acids in
cell culture (SILAC) proteomics in the 32D murine hematopoietic
progenitor cell line (Ong et al., 2002; Ward et al., 1999). To
do this, we expressed either miR-125a, miR-125mut4T/C or a
control vector and cultured cells in media with isotope-labeled
amino acids (Figure 5A). We detected a total of 4,789 ex-
pressed proteins in duplicate experiments when analyzing
fold-change expression ratios, comparing cells expressing
the control vector with those expressing miR-125a and control
vector with 125mut4T/C samples. As the induction of a long-
term repopulating program in HSPCswas largely seed sequence
dependent, we excluded proteins that were similarly affected by
both miR-125a and 125mut4T/C. This filtered out previously re-
ported miR-125 targets such as Bak 1, Traf 6, Klf13, and Bmf
(Guo and Scadden, 2010; O’Connell et al., 2010; Ooi et al.,
2010) (Figure 5B). We identified 217 proteins that were differen-
tially expressed upon miR-125a overexpression. Of these, 11
genes contained a 30 UTR target sequence that is perfectly
complementary to the seed sequence of miR-125 (Figure 5C);
ten targets showed decreased protein levels upon miR-125a
overexpression in our cell system andwere therefore considered
to be direct miR-125 targets. These targets include p38 kinase,
a negative HSC self-renewal regulator (Ito et al., 2006), and
its inhibition leads to ex vivo HSC expansion (Wang et al.,
2011), three protein tyrosine phosphatases (Ptpn1, Ptpn7, and
Smek1, all known to suppress cytokine signaling and negatively
regulate MAP kinases), a ubiquitin ligase (Syvn1, shown to block
differentiation of embryonic stem cells; Yagishita et al., 2005),
and Vps4b and M6pr, which are involved in transport of protein
to vesicles and their lysosomal degradation. In addition, we iden-
tified interleukin-16 (IL-16) and Txnrd1, the latter gene playing a
role in protection against oxidative stress (Peng et al., 2014).
To gain further insight into the mechanism whereby miR-125a
was exerting its biological effects on human HSPCs, we per-
formed label-free protein mass spectrometry on 100,000 sorted
mO+CD34+ human cord blood (huCB) HSPCs transduced with
miR-125a or control vector. We were able to reliably quantify
6,687 protein groups (Figure S5D), and 517 of them showed
a significant change (p < 0.05) between 125OE and control
samples (Table S3). Gene set enrichment analysis (GSEA) of
the proteomics dataset identified pathways and leading edge
genes directly targeted by miR-125a. In post-analysis, predictedIncreases the Self-Renewal Potential
transduced with miR-125mut4T/C (n = 7), LT-HSCs with control vector (n = 11),
f B220+, CD3ε+, or Gr-1+ cells in 106 viable peripheral blood cells, assessed by
ontrol vector (n = 17) or miR-125a (n = 9), measured by FACS at indicated time
progenitor cell populations, measured by limiting dilution. Confidence intervals
tal groups and are the same throughout all figures.
requency of repopulating cells, calculated using ELDA.
weeks post-transplantation.
using a non-parametric Mann-Whitney test, where *p < 0.05, **p < 0.01, and
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miR-125a targets were correlated with proteomic-modulated
pathways (Figure 5D). The most significant pathways centered
on JUN kinase activation, FAS signaling, stress-activated
kinase signaling, Toll-like receptor signaling, interferon gamma
signaling, and the NoRC complex, an epigenetic pathway
involved in heterochromatin formation (Figures 5D and 5E).
These data suggest that miR-125 exerts its effects on HSPCs
by downregulating several genes within multiple pathways. Our
data also confirm that P38MAPK14 and PTPN1 are miR-125a
targets in both murine and human HSPCs.
To validate identified targets, we performed nanofluidic prote-
omic analysis and confirmed the suppression of p38, Ptpn1 and
Ptpn7, and Vps4b in cell lines used for SILAC (Figure S6A). To
assess the downregulation of miR-125a targets in human
CD34+ and mouse LT-HSCs and progenitors overexpressing
miR-125a, we measured the expression of p38, Ptpn1, and
Ptpn7, as well as Smek1 transcripts, by qPCR. We confirmed
that all tested targets showed decreased expression compared
to controls in both mouse and human cells (Figures 6A, 6B, and
6E). We were also able to verify the repression of these targets at
the protein level by western blot or immunofluorescence in trans-
duced human CD34+ CB cells or sorted and transduced mouse
LT-HSCs and progenitors (Figures 6C, 6D, and 6F). Together,
these data suggest that the endowment of an HSC-like self-
renewal program in hematopoietic progenitors that normally
lack self-renewal capacity upon miR-125a overexpression is
linked to repression of genes controlling the p38/mitogen-acti-
vated protein kinase (MAPK) pathway as well as several other
pathways. Furthermore, our results reinforce the notion that
miR-125a exerts similar functions in mouse and human cells.
DISCUSSION
Our study provides key insights into the powerful role that miR-
NAs can play in the regulation of HSC expansion/self-renewal
properties. Previous work demonstrated expansion of the HSC
pool upon miR-125 expression (Ooi et al., 2010). Here, we
establish that miR-125a can endow repopulation potential to
progenitor populations and potently increase their self-renewal
capacity. Our findings highlight the possibility of generating
MPPs with enhanced self-renewal to augment limited sourcesFigure 4. Enforced miR-125a Ectopic Expression Sustains Repopulatio
(A) The number of donor-derived GFP+ B220+, CD3ε+, or Gr-1+ cells per 106 perip
with LT-HSCs transduced with control vector (n = 5) or miR-125a (n = 5).
(B) The number of donor-derived GFP+ B220+, CD3ε+, or Gr-1+ cells per 106 perip
with progenitors transduced with control vector (n = 3) or miR-125a (n = 5). D
parametric Mann-Whitney test in case of Gr-1+ cells.
(C) Peripheral blood lineage distribution of GFP+ cells in secondary recipients.
(D) Peripheral blood Gr-1+ chimerism levels in secondary recipients 20 weeks po
(E) The lifespan of transduced cells (plotted mice were considered positive if the
(F) The survival statistics of primary, secondary, and tertiary recipients transplant
x axis indicate time points of serial transplantations.
(G) Representative FACS plot of the LinSca-1+ c-kit+ compartment in BM cells
Right panel shows repopulation potential of indicated cell population assessed i
(H) Same as (G), but for progenitors overexpressing miR-125a.
(I) Experimental setup for the second model, non-conditioned W41 mice used as
(J) The kinetics of chimerism changes in Gr-1+ cells in the course of experiment.
(K) The survival curve of non-irradiated W41 recipients transplanted with control
All data reflect mean values ± SD, except for (K), which shows mean values ± SEM
test, where *p < 0.05, **p < 0.01, and ***p < 0.001.of HLA-matched CB-derived HSCs to improve transplant out-
comes. As CB-transplant-related mortality is influenced by low
numbers of infused HSCs, rapid in vitro expansion of CB progen-
itors could increase the transplanted dose of stem cells, thus
accelerating engraftment and reducing complications. Although
it may be possible to therapeutically employ miR-125a to confer
MPPs with self-renewal capacity, it is more likely that small-
molecule regulation of several critical miR-125a targets will be
required to fully translate our work. In the future, combinatorial
approaches combining miR-125a modified MPPs with existing
small-molecule compounds like PGE2, SR1, and UM171 (Boi-
tano et al., 2010; Fares et al., 2014; North et al., 2007) may sup-
port expansion of undersized HLA-matched CB units, allowing
them to become a selected source of cells for transplantation.
The development of myeloproliferative disease/leukemia upon
miR-125a overexpression in murine cells in secondary and ter-
tiary recipients is in agreement with previous reports (Bousquet
et al., 2010; Gerrits et al., 2012; O’Connell et al., 2010) and
has been shown to be dependent upon sustained expression
of miR-125a (Guo et al., 2012) and dosage (O’Connell et al.,
2008, 2010). Our data suggest the miR-125a-induced myelopro-
liferative disease occurs, in part, as a function of replicative
stress. We surmise that with careful titration of miR-125 levels,
it may be possible to exploit the beneficial self-renewal effects
of miR-125 without incurring the malignant side effects. Interest-
ingly, overt malignancy was never observed in human xenografts
through three serial transplantations (30 weeks total), suggesting
that the inherent susceptibility of murine cells to oncogenic
transformation may contribute to the development of (pre-) ma-
lignancy (Balmain and Harris, 2000; Rangarajan et al., 2004). We
cannot completely discount the possibility that vector integration
contributed tomalignant transformation. However, we deem this
unlikely, considering the reproducibility of the acquired pheno-
types and the absence of any known strong oncogenes in inser-
tion site analysis. In addition, our data on cellular barcoding
confirm that mice transplanted with LT-HSCs or progenitors
overexpressing miR-125a had polyclonal repopulation similar
to control LT-HSC, excluding the possibility that engraftment
results from clonal dominance of a single clone.
We found similar behavior between control HSCs and miR-
125a-transduced MPPs regarding their long-term multi-lineagen Potential to MPPs in Serial Transplantation
heral blood cells at indicated time points in secondary recipients transplanted
heral blood cells at indicated time points in secondary recipients transplanted
ata reflect mean values ± SEM. Statistical significance assessed using non-
st-transplantation.
percentage of Gr-1+ was >1%; brakes indicate serial transplantations).
ed with LT-HSCs or progenitors overexpressing miR-125a. Interruptions of the
from primary recipients transplanted with LT-HSCs overexpressing miR-125a.
n secondary recipients. Donor cells were obtained from three mice.
recipients.
or miR-125a-overexpressing LT-HSCs.
. Statistical significance was assessed using a non-parametric Mann-Whitney
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Figure 6. Target Validation
(A–D) Validation of selected targets in mouse
transduced LT-HSC or progenitors at the transcript
level (A and B) and protein level (C and D).
(E and F) Repression of miR-125a targets in human
CD34+ cells at the transcript level (E) and protein
level (F).
All data reflect mean values ± SEM. Statistical
significance was assessed using a non-parametric
Mann-Whitney test, where *p < 0.05, **p < 0.01,
and ***p < 0.001.repopulating ability, self-renewal potential, and lineage distribu-
tion in transplanted recipients,both inmouseandhumansystems.
This similarity points to a commonmechanismwherebymiR-125a
functions to govern stem cell properties. Using proteomic anal-
ysis, we uncovered a subset of the relevant miR-125a-targeted
pathways. Our study predicts that several of our identified targets
should normally act to repress self-renewal in cells downstream
of HSCs. Of the ten identified targets in murine cells, four are
involved in the MAPK signaling pathway. The best-known and
most-studied candidate protein is p38. Chemical inhibitors of
p38 activity have previously shown efficacy in ex vivo mouse
and human HSC expansion protocols (Baudet et al., 2012;
Wang et al., 2011). Another candidate target is PTPN1, of which
little is known in the hematopoietic system. Loss of PTPN1 leads
to increased numbers of pro- and pre-B cells in the BM (Dube´
et al., 2005), similar to previous reports showing increased
numbers of pro-B cells upon miR-125b overexpression (Chaud-
huri et al., 2012) and correlating with our human CB xenotrans-
plantation data. Moreover, deletion of PTPN1 in fibroblasts leads
to suppression of Erk signaling (Dube´ et al., 2004) and increased
insulin growth factor-1 (IGF-1)-induced AKT protein kinase B
activity (AKT/PKB) (Buckley et al., 2002). Constitutive activation
of AKT in HSPCs has been shown to deplete B lymphocytes
and induce myeloid skewing and the development of myelo-Figure 5. Molecular Mechanism of Sustained Self-Renewal Potential in Human and Mouse MP
(A) SILAC experimental setup. 32D cells were transduced with control vector, miR-125a, or 125mut4T/C. Cel
125a OE or miR-125mut4T/C samples) or heavy labeled amino acids (empty vector [EV]), as indicated.
(B) Graphical representation of 217 differentially expressed proteins. Blue symbols indicate previously rep
indicate the ten differentially expressed seed-sequence-containing proteins in miR-125a and 125mut4T/C s
(C) Overview of filtering criteria.
(D) Functional enrichmentmap for proteinMS-based expression revealingmiR-125amodulated pathways in h
that were found to have a significant overlap with miR-125a targets is shown. Blue nodes (circles) represe
CD34+ human cord blood cells overexpressing miR-125a. Green line (edge) width between nodes correspon
125a targets (yellow triangle) are connected to enriched pathways by pink edges and edge width is prop
[lesser] proteomics p = < 0.01).
(E) Top six pathways significantly downregulated by miR-125a expression. Columns represent individual
underneath. Protein names in blue are predicted miR-125a targets.
Cell Stemproliferative disorders that progressed
to leukemia (Helgason et al., 1998; Zhang
et al., 2006). We speculate that PTPN1
downregulation may similarly activate
AKT in HSPCs, resulting in myeloid skew-
ing and a block in B cell differentiation.
However, the exact direct and indirect
contribution of each individual miR-125a
target in moderating self-renewal activitywithin progenitors requires additional studies. Multiple targets
within several pathways are probably required to fully recapitulate
the effects of miR125a on MPPs.
Irrespective of the precise mechanism of action, our findings
provide clear evidence that miR-125a confers hematopoietic
stem cell potential to cells that are normally devoid of this activ-
ity. Our results open the prospect of searching for other regula-
tors that have this capability laying the foundation for utilizing
progenitors in clinically relevant therapeutics. Molecular identi-
fication and functional evaluation of the full complement of
miR-125a targets may allow the dissection of targets inhibiting
self-renewal and distinguishing them from targets that may
be closely aligned with malignancy. Furthermore, small-mole-
cule screening and candidate identification on hematopoietic
progenitor populations using induction of miR-125a as an oper-
ational readout could circumvent the requirement for virally en-
forced miRNA expression and accelerate the clinical application
of miR-125a for CB transplantation.EXPERIMENTAL PROCEDURES
Cell Sorting
Human Lin CB cells were thawed and stained with CD34-APC-Cy7 and
CD38-PE-Cy7 (BD). For HSC, MPP, andMLP sorts, LinCB cells were stainedPs
ls were cultured in medium containing normal (miR-
orted targets of the miR-125 family. Red symbols
amples.
umanCD34+CB cells. Only the subset of pathways
nt gene sets enriched in proteins downregulated in
ds to the number of shared proteins. PredictedmiR-
ortional to the overlap significance (Mann-Whitney
pathways, with the protein names listed vertically
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with CD34, CD38, CD49f, CD45RA, CD90, CD7, and CD10. Murine BM cells
were isolated by crushing and then stained with a cocktail of antibodies
against lineage markers (Ter119, Gr-1, Mac-1, CD3, and B220), c-Kit, Sca-1,
CD48, and CD150 and sorted for LT-HSCs (LinSca-1+c-Kit+CD150+48)
and progenitors (LinSca-1+c-Kit+ depleted from CD150+48 cells).
Lentiviral and Retroviral Constructs and Transduction
For the human part of the study, the lentiviral vector for ectopic miRNA expres-
sion (gain of function) has been described previously (Gentner et al., 2010).
In the murine part of the study, we used a retroviral vector, miR-125a, and
mut 4T/C cells were cloned as previously described (Gerrits et al., 2012; Woj-
towicz et al., 2014).
NSG Repopulation Assay
Male NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; Jackson Laboratory)
were sublethally irradiated (225 cGy) 24 hr before intrafemoral injection.
Competitive transplantation was performed using the equivalent of 400
HSCs, 400 MPPs, and 1,000 MLP cells after overnight culture in low-cytokine
conditions. Limiting dilution analysis of human CD34+/CD38CB cell was per-
formed a secondary mouse was scored as positive if it had >0.5% hCD45+,
mOrange+ BM engraftment 8 weeks post transplantation. HSC frequency
was estimated using ELDA software (http://bioinf.wehi.edu.au/software/
elda/; Hu and Smyth, 2009).
C57BL/6 (B6) mice were purchased from Harlan Laboratories. C57BL/6.SJL
mice were bred at the Central Animal Facility of University Medical Centre
of Groningen (Groningen, the Netherlands). All animal experiments were
approved by the University of Groningen Animal Care Committee.
Lentiviral Insertion Site Analysis by Modified Splinkerette PCR
To determine the lentiviral integration sites we used a splinkerette PCR
approach (Uren et al., 2009) that we modified to be non-restrictive and have
increased sensitivity for low DNA input amounts (see Supplemental Experi-
mental Procedures). For identified integration sites in MPP-engrafted mice,
see Table S1.
Cellular Barcoding
Cells were isolated and transduced as described above (see also Verovskaya
et al., 2013). We transplanted 15,760 GFP+ progenitor cells per mouse and
4,300 GFP+ LT-HSCs overexpressing miR-125a, 39,800 GFP+ progenitors,
or 16,200 GFP+ LT-HSCs for controls.
Hematopoietic Cell Transplantation and Blood Analysis
For limiting dilution experiments, cells were injected in given doses (Fig-
ure S3A) into lethally irradiated (9 Gy) female B6 recipients together with
2 3 106 fresh BM B6 cells. Blood samples were taken every 4–6 weeks
and stained with antibodies against CD45.1 and CD45.2 to determine
the donor chimerism and CD3ε, Gr-1, and B220 for FACS analysis. HSC
frequency was estimated using ELDA software (http://bioinf.wehi.edu.au/
software/elda/).
Serial BM Transplantation
Primary recipients were sacrificed at 16 weeks post-transplantation for BM
collection prior to secondary transplantation. 107 whole BM cells were trans-
planted into lethally irradiated secondary recipients. For tertiary recipients, do-
nors were sacrificed 24 weeks post-secondary transplantation, and 5 3 106
whole BM cells were injected together with 5 3 105 fresh competitor cells
from B6.
qPCR
RNA was extracted from 25,000 to 30,000 GFP+ cells using the miRNeasy Kit
(QIAGEN), and commercially available TaqMan probes for miRNA qPCR or
primers (Table S4) were used according to the manufacturer’s protocol.
Label-free Quantitative Proteomics Analysis
The raw files were analyzed using MaxQuant version 1.5.2.8 (Cox and
Mann, 2008) and standard settings. For differentially expressed proteins,
see Table S3. For sample preparation details, see Supplemental Experimental
Procedures.394 Cell Stem Cell 19, 383–396, September 1, 2016Quantitative Mass Spectrometry: SILAC
The murine 32D cell line was used for to identify miR-125a targets. After trans-
duction, GFP+ cells were FACS sorted and expanded prior to stable isotope
labeling as previously reported (Meenhuis et al., 2011). A nano-high perfor-
mance liquid chromatography (HPLC) system consisting of Easy-nLC 1000
and Q-Exactive (Thermo Fisher Scientific) was used.
Statistical Analysis
Unless otherwise stated, mean ± SEM values are shown in the graphs. For
pairwise comparison, a Mann-Whitney U test was applied. Statistical analysis
was performed using PRISM 6 (GraphPad Software). For proteomics data
analysis, Student’s t test with Bonferroni correction was applied.
Western Blot Analysis
For immunoblotting, proteins were transferred to PVDF membranes, incu-
bated with the specific antibody (anti-p38, Cell Signaling #9212 1:1,000;
anti-PTPN1, LifeSpan BioSciences #LS-C61924 1:500; and mouse anti-
GAPDH, 1:10,000, Sigma) followed by peroxidase-conjugated secondary
antibodies. Bands were visualized on Amersham Hyperfilm (GE Healthcare).
Nanofluidic Proteomic Analysis
The expression levels of p38 in transducedGFP+ 32D cells used for SILAC or in
LT-HSCs and progenitors overexpressing miR-125a were investigated by a
size-basedSimplewestern immunoassay, using aWESdevice (ProteinSimple).
Immunofluorescence
To measure protein expression levels in transduced GFP+ LT-HSC or progen-
itors (Lin-Sca-1+c-Kit+ depleted from CD150+ 48- cells), cells were stained
with antibodies directed against p38 (1:50, Cell Signaling, #9212) and Ptpn1
(1:100, Millipore, clone# ABS40). We used rabbit-specific IgG conjugated
with Alexa-633 (Molecular Probes, Invitrogen) as a secondary antibody. For
nuclear staining we treated cells with DAPI (Sigma).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.stem.2016.06.008.
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